Table A2.

Progression-Free Survival by TOP2AGene Amplification Status for Test Set Patients Treated in the H0648 Trial

Parameter	TOP2AStatus by Regimen
	AC Alone		AC + H		Any AC
	Not Amplified	Amplified	Not Amplified	Amplified	Not Amplified	Amplified
No.	50	27	54	31	104	58
Censored	3	3	14	11	17	14
%	6	11	24	35	16	24
Median, months	5.6*	7.1†	7.3*	8.6†	6.7	7.6
95% CI	4.6 to 6.7	4.7 to 9.8	6.9 to 9.4	7.1 to 12.7	5.6 to 7.3	7.1 to 9.8
Log-rank P	.11		.31		.064‡

Abbreviations: A, doxorubicin; C, cyclophosphamide; H, trastuzumab.

^*Differences have a P = .0026.

^†Differences have a P = .0344.

^‡P is based on stratified log-rank; stratification variable is treatment with trastuzumab.